Gregory A. Otterson, MD, on Adjuvant Therapy and Immunotherapy for Lung Cancer 
    		2015 NCCN Annual Conference
    	
    	
    	
    
        Gregory A. Otterson, MD, of The Ohio State University Comprehensive Cancer Center and the James Cancer Hospital and Solove Research Institute, discusses the evolution of lung cancer treatment from adjuvant chemotherapy to immunotherapy and the clinical trials underway.
    
    
    
    
       
       
    		Leora Horn, MD, MSc
		
		
        
		
		
		
		Leora Horn, MD, MSc, of the Vanderbilt-Ingram Cancer Center, discusses the range of treatment options for people with lung cancer, including third generation inhibitors, and the key clinical trials studying alternatives for patients with acquired resistance.
			
			
     	
    
       
       
    		Axel Grothey, MD
		
		
        
		
		
		
		Axel Grothey, MD, of the Mayo Clinic Cancer Center, discusses how the NCCN Guidelines can help oncologists make strategic choices of the various agents available to treat metastatic colorectal cancer, individualizing patient care.
			
			
     	
    
       
       
    		Anthony J. Olszanski, RPh, MD
		
		
        
		
		
		
		Anthony J. Olszanski, RPh, MD, of the Fox Chase Cancer Center, discusses the advances in immunotherapy generally and for melanoma in particular.
			
			
     	
    
       
       
    		John A. Thompson, MD
		
		
        
		
		
		
		John A. Thompson, MD, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discusses the latest immunotherapeutics for advanced melanoma, including pembrolizumab, trametinib, nivolumab, and dabrafenib.
			
			
     	
    
       
       
    		Hans Gerdes, MD
		
		
        
		
		
		
		Hans Gerdes, MD, of Memorial Sloan Kettering Cancer Center, discusses a new approach to the management of early-stage esophageal cancers with endoscopic resections.